These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9812202)

  • 41. Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins.
    Aviram M
    Antioxid Redox Signal; 1999; 1(4):585-94. PubMed ID: 11233155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.
    Borén J; Olin K; Lee I; Chait A; Wight TN; Innerarity TL
    J Clin Invest; 1998 Jun; 101(12):2658-64. PubMed ID: 9637699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipoprotein receptors and atherosclerosis.
    Kostner GM
    Biochem Soc Trans; 1989 Aug; 17(4):639-41. PubMed ID: 2548904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion.
    Lieu HD; Withycombe SK; Walker Q; Rong JX; Walzem RL; Wong JS; Hamilton RL; Fisher EA; Young SG
    Circulation; 2003 Mar; 107(9):1315-21. PubMed ID: 12628954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of low density lipoprotein receptor eliminates apolipoprotein B100-containing lipoproteins from circulation and markedly prevents early atherogenesis in apolipoprotein E-deficient mice.
    Murayama T; Yokode M; Horiuchi H; Yoshida H; Sano H; Kita T
    Atherosclerosis; 2000 Dec; 153(2):295-302. PubMed ID: 11164418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque.
    Pal S; Semorine K; Watts GF; Mamo J
    Clin Chem Lab Med; 2003 Jun; 41(6):792-5. PubMed ID: 12880143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of triglyceride-rich lipoproteins in atherogenesis.
    Zilversmit DB
    Ann N Y Acad Sci; 1976; 275():138-44. PubMed ID: 188364
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Receptor endocytosis of polyenic acids: sensitivity and resistance to atherosclerosis (review of the literature)].
    Titov VN
    Klin Lab Diagn; 1999 Jan; (1):3-8. PubMed ID: 10097487
    [No Abstract]   [Full Text] [Related]  

  • 49. Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding.
    Sánchez-Quesada JL; Villegas S; Ordóñez-Llanos J
    Curr Opin Lipidol; 2012 Oct; 23(5):479-86. PubMed ID: 22964994
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Retention of apolipoprotein B and cholesterol by perfused heart during lipolysis of very-low-density lipoprotein.
    Tam SP; Breckenridge WC
    Biochim Biophys Acta; 1984 Mar; 793(1):61-71. PubMed ID: 6704414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.
    Véniant MM; Zlot CH; Walzem RL; Pierotti V; Driscoll R; Dichek D; Herz J; Young SG
    J Clin Invest; 1998 Oct; 102(8):1559-68. PubMed ID: 9788969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.
    Véniant MM; Withycombe S; Young SG
    Arterioscler Thromb Vasc Biol; 2001 Oct; 21(10):1567-70. PubMed ID: 11597927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis.
    Khalil MF; Wagner WD; Goldberg IJ
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2211-8. PubMed ID: 15472124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis.
    Hurt-Camejo E; Olsson U; Wiklund O; Bondjers G; Camejo G
    Arterioscler Thromb Vasc Biol; 1997 Jun; 17(6):1011-7. PubMed ID: 9194748
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100.
    Boren J; Lee I; Zhu W; Arnold K; Taylor S; Innerarity TL
    J Clin Invest; 1998 Mar; 101(5):1084-93. PubMed ID: 9486979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retention of oxidized LDL by extracellular matrix proteoglycans leads to its uptake by macrophages: an alternative approach to study lipoproteins cellular uptake.
    Kaplan M; Aviram M
    Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):386-93. PubMed ID: 11231918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostaglandin E1 decreases human arterial accumulation of radiolabeled apo B-containing lipoproteins in vivo.
    Kritz H; Sinzinger H; Lupattelli G; Virgolini I; Fitscha P; O'Grady J
    Eur J Clin Pharmacol; 1997; 52(3):191-7. PubMed ID: 9218925
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Lipid metabolism in atherogenesis].
    Bobková D; Poledne R
    Cesk Fysiol; 2003 Feb; 52(1):34-41. PubMed ID: 12693188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atherogenesis: a postprandial phenomenon.
    Zilversmit DB
    Circulation; 1979 Sep; 60(3):473-85. PubMed ID: 222498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.